CoChat

Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature

Fonseka, Trehani M., Richter, Margaret A., Müller, Daniel J. · 2014 · Current Psychiatry Reports

The DOI matches its Crossref record; 185 of the 186 references it cites were found in a registry or an index.

Abstract

Second generation antipsychotics (SGAs) have been implicated in the de novo emergence and exacerbation of obsessive-compulsive symptoms (OCS) in patients with schizophrenia. Among SGAs, clozapine, olanzapine, and risperidone are the most prominent agents associated with these sequelae, according to case reports. Comorbid OCS can impede recovery by compromising treatment benefits, medication compliance, and clinical prognoses. Previous reviews of SGA-induced OCS have predominantly focused on descriptive case reports, with limited attention paid toward experimental findings. To address this paucity of data, we sought to review the effects of SGAs on OCS in schizophrenia in the experimental literature, while addressing the role of different treatment (duration, dose, serum levels) and pharmacogenetic factors. Our findings suggest that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28% of clozapine-treated patients experiencing de novo OCS, in addition to 10 to 18% incurring an exacerbation of pre-existing OCS. Clozapine can also yield full threshold obsessive-compulsive disorder (OCD), in some cases. Olanzapine is another high risk drug for secondary OCS which occurs in 11 to 20% of schizophrenic patients receiving olanzapine therapy. At this time, there is insufficient experimental evidence to characterize the effects of other SGAs on OCS. Despite some experimental support for the involvement of longer treatment duration and genetic factors in mediating drug-induced OCS, more research is needed to clearly elucidate these associations. Based on these results, schizophrenic patients should be routinely monitored for OCS throughout the course of SGA treatment, particularly when clozapine or olanzapine is administered.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11920-014-0510-8

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 185 references

Research works printed but not linked: 1

  1. Aggarwal A, Sharma D, Sharma R, Kumar R. Obsessive-compulsive symptoms following clozapine administration. Prim Psychiatry. 2010;17(3):58–9.

Cited by

See all 93

Metadata

Authors
Fonseka, T. M., Richter, M. A., & Müller, D. J.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • Sunnybrook Health Science Centre (CA)
Corresponding author
Müller, Daniel J.
Venue
Current Psychiatry Reports
Published
2014-09-26
Volume
16
Issue
11
Pages
510-510
ISSN
  • 1523-3812 (ISSN-L)
  • 1535-1645
OpenAlex
W2002363278
Cited by
93
References
186
Citations by year
2026: 5 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 9 · 2017: 4 · 2016: 9 · 2015: 5
FWCI
0.83
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Psychiatry Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords
atypical antipsychotics, obsessive-compulsive symptoms, schizophrenia, clozapine, olanzapine, risperidone, pharmacogenetics, treatment duration, serum drug concentration, adverse drug reactions, symptom exacerbation
MeSH terms
Humans, Obsessive-Compulsive Disorder, Schizophrenia, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature. https://app.cochat.ai/papers/10.1007/s11920-014-0510-8
The paper
Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014). Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature. Current Psychiatry Reports. https://doi.org/10.1007/s11920-014-0510-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.